Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-4: adagrasib plus pembrolizumab plus chemotherapy versus placebo plus pembrolizumab plus chemotherapy in untreated KRAS G12C-mutated non-squamous NSCLC
NL-OMON59148Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2025; status: recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59148.